Angiogenesis in arthritis: Role in disease pathogenesis and as a potential therapeutic target

Angiogenesis

Volumn 2, Issue 4, 1998, Pages 295-307

  Paleolog, Ewa M ^a,b   Miotla, Jadwiga M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Angiogenesis; Arthritis; Inflammation; VEGF

Indexed keywords

MURINAE;

EID: 0000923770     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009229508096     Document Type: Review

References (71)

1. Harris ED, Jr. Pathogenesis of rheumatoid arthritis. Am J Med 1986; 80, 4-10.
2. Johnston SA. Osteoarthritis. Joint anatomy, physiology, and pathobiology. Vet Clin North Am Small Anim Pract 1997; 27, 699-723.
3. Sewell KL, Trentham DE. Pathogenesis of rheumatoid arthritis. Lancet 1993; 341, 283-286.
4. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996; 85, 307-310.
5. Colville-Nash P, Scott DL. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992; 51, 919-925.
6. Stevens CR, Blake DR, Merry P, et al. A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium. Arthritis Rheum 1991; 34, 1508-1513.
7. Brown RA, Weiss JB, Tomlinson IW, et al. Angiogenic factor from synovial fluid resembling that from tumours. Lancet 1980; 1 (8170), 682-685.
8. Semble EL, Turner RA, McCrickard EL. Rheumatoid arthritis and Osteoarthritis synovial fluid effects on primary human endothelial cell cultures. J Rheumatol 1985; 12, 237-241.
9. Ceponis A, Konttinen YT, Imai S, et al. Synovial lining, endothelial and inflammatory mononuclear cell proliferation in synovial membranes in psoriatic and reactive arthritis: a comparative quantitative morphometric study. Br J Rheumatol 1998; 37, 170-178.
10. Walsh DA, Wade M, Mapp PI, Blake DR. Focally regulated endothelial proliferation and cell death in human synovium. Am J Pathol 1998; 152, 691-702.
11. Rooney M, Condell D, Quinlan W, et al. Analysis of the histologie variation of synovitis in rheumatoid arthritis. Arthritis Rheum 1988; 31, 956-963.
12. Jalkanen S, Steere AC, Fox RI, Butcher EG. A distinct endothelial cell recognition system that controls lymphocyte traffic into inflamed synovium. Science 1986; 233, 556-558.
13. Koch AE. Review: angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum 1998; 41, 951-962.
14. Szekanecz Z, Szegedi G, Koch AE. Angiogenesis in rheumatoid arthritis: pathogenic and clinical significance. J Investig Med 1998; 46, 27-41.
15. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1995; 1, 27-31.
16. Stevens CR, Williams RB, Farrell AJ, Black DR. Hypoxia and inflammatory synovitis: observations and speculation. Ann Rheum Dis 1991; 50, 124-132.
17. Blake DR, Merry P, Unsworth J, et al. Hypoxic-reperfusion injury in the inflamed human joint. Lancet 1989; 1 (8633), 289-293.
18. Treuhaft PS, McCarty DJ. Synovial fluid pH, lactate, oxygen and carbon dioxide partial pressure in various joint diseases. Arthritis Rheum 1971; 14, 475-484.
19. Kiaer T, Gronlund J, Sorensen KH. Subchondral pO2, pCO2, pressure, pH, and lactate in human osteoarthritis of the hip. Clin Orthop 1988; 149-155.
20. Sano H, Forough R, Maier JA, et al. Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints. J Cell Biol 1990; 110, 1417-1426.
21. Sano H, Engleka K, Mathern P, et al. Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis. J Clin Invest 1993; 91, 553-565.
22. Qu Z, Huang XN, Ahmadi P, et al. Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease. Lab Invest 1995; 73, 339-346.
23. Montesano R, Vassalli JD, Baird A, et al. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 1986; 83, 7297-7301.
24. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biockem Biophys Res Commun 1992; 189, 824-831.
25. Koch AE, Halloran MM, Hosaka S, et al. Hepatocyte growth factor. A cytokine mediating endothelial migration in inflammatory arthritis. Arthritis Rheum 1996; 39, 1566-1575.
26. Rubin K, Terracio L, Ronnstrand L, et al. Expression of platelet-derived growth factor receptors is induced on connective tissue cells during chronic synovial inflammation. Scand J Immunol 1988; 27, 285-294.
27. Remmers EF, Sano H, Lafyatis R, et al. Production of platelet derived growth factor B chain (PDGF-B/c-sis) mRNA and immunoreactive PDGF B-like polypeptide by rheumatoid synovium: coexpression with heparin binding acidic fibroblast growth factor-1. J Rheumatol 1991; 18, 7-13.
28. Waguri Y, Otsuka T, Sugimura I, et al. Gliostatin/ platelet-derived endothelial cell growth factor as a clinical marker of rheumatoid arthritis and its regulation in fibroblast-like synoviocytes. Br J Rheumatol 1997; 36, 315-321.
29. Takeuchi M, Otsuka T, Matsui N, et al. Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid synovium. Arthritis Rheum 1994; 37, 662-672.
30. Chu CQ, Field M, Allard S, et al. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 1992; 31, 653-661.
31. Taketazu F, Kato M, Gobi A, et al. Enhanced expression of transforming growth factor-betas and transforming growth factor-beta type II receptor in the synovial tissues of patients with rheumatoid arthritis. Lab Invest 1994; 70, 620-630.
32. Kuruvilla AP, Shah R, Hochwald GM, et al. Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci USA 1991; 88, 2918-2921.
33. Wahl SM, Allen JB, Costa GL, et al. Reversal of acute and chronic synovial inflammation by anti-transforming growth factor beta. J Exp Med 1993; 177, 225-230.
34. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 1994; 269, 6271-6274.
35. Fava RA, Hunt JA, Yeo KT, et al. Induction of vascular permeability factor (vascular endothelial growth factor) by TGFβ in synovial fibroblasts. Arthritis Rheum 1995; 38, S343.
36. Shiozawa S, Shiozawa K, Tanaka Y, et al. Human epidermal growth factor for the stratification of synovial lining layer and neovascularisation in rheumatoid arthritis. Ann Rheum Dis 1989; 48, 820-828.
37. Keyszer GM, Heer AH, Kriegsmann J, et al. Detection of insulin-like growth factor I and II in synovial tissue specimens of patients with rheumatoid arthritis and osteoarthritis by in situ hybridization. J Rheumatol 1995; 22, 275-281.
38. Brown LF, Detmar M, Claffey K, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997; 79, 233-269.
39. Paleolog EM. Angiogenesis: a critical process in the pathogenesis of RA - a role for VEGF? Br J Rheumatol 1996; 35, 917-919.
40. 2+ and von Willebrand factor release in human endothelial cells. Am J Pathol 1991; 138, 213-221.
41. Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994; 152, 4149-4156.
42. Fava RA, Olsen NJ, Spencer-Green G, et al. Vascular permeability factor/endothelial growth factor (VPF/ VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994; 180, 341-346.
43. Nagashima M, Yoshino S, Ishiwata T, Asano G. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 1995; 22, 1624-1630.
44. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359, 843-845.
45. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997; 94, 8761-8766.
46. Paleolog EM, Young S, Stark AC, et al. Modulation of angiogenic vascular endothelial growth factor (VEGF) by TNFα and IL-1 in rheumatoid arthritis. Arthritis Rheum 1998; 41, 1258-1265.
47. Hosaka S, Akahoshi T, Wada C, Kondo H. Expression of the chemokine superfamily in rheumatoid arthritis. Clin Exp Immunol 1994; 97, 451-457.
48. Brennan FM, Zachariae CO, Chantry D, et al. Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur J Immunol 1990; 20, 2141-2144.
49. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258, 1798-1801.
50. Koch AE, Kunkel SL, Harlow LA, et al. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 1994; 94, 1012-1018.
51. Koch AE, Kunkel SL, Shah MR, et al. Growth-related gene product alpha. A chemotactic cytokine for neutrophils in rheumatoid arthritis. J Immunol 1995; 155, 3660-3666.
52. Koch AE, Halloran MM, Haskell CJ, et al. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995; 376, 517-519.
53. DiPietro LA, Nebgen DR, Polverini PJ. Downregulation of endothelial cell thrombospondin 1 enhances in vitro angiogenesis. J Vasc Res 1994; 31, 178-185.
54. DiPietro LA, Polverini PJ. Angiogenic macrophages produce the angiogenic inhibitor thrombospondin 1. Am J Pathol 1993; 143, 678-684.
55. Frater-Schroder M, Risau W, Hallmann R, et al. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987; 84, 5277-5281.
56. Brennan FM, Chantry D, Jackson A, et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2 (8657), 244-247.
57. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997; 17, 4015-4023.
58. Lupia E, Montrucchio G, Battaglia E, et al. Role of tumor necrosis factor-alpha and platelet-activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis. Eur J Immunol 1996; 26, 1690-1694.
59. Paleolog EM, Hunt M, Elliott MJ, et al. Deactivation of vascular endothelium by monoclonal antitumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 1996; 39, 1082-1091.
60. Hosaka S, Shah MR, Barquin N, et al. E. Expression of basic fibroblast growth factor and angiogenin in arthritis. Pathobiology 1995; 63, 249-256.
61. Takada T, Toriyama K, Muramatsu H, et al. Midkine, a retinoic acid-inducible heparin-binding cytokine in inflammatory responses: chemotactic activity to neutrophils and association with inflammatory synovitis. J Biochem (Tokyo) 1997; 122, 453-458.
62. Millauer B, Longhi MP, Plate KH, et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996; 56, 1615-1620.
63. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92, 10457-10461.
64. Cheng SY, Huang HJ, Nagane M, et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1996; 93, 8502-8507.
65. Hirata S, Matsubara T, Saura R, et al. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989; 32, 1065-1073.
66. Koch AE, Cho M, Burrows J, et al. Inhibition of production of macrophage-derived angiogenic activity by the anti-rheumatic agents gold sodium thiomalate and auranofin. Biochem Biophys Res Commun 1988; 154, 205-212.
67. Koch AE, Burrows JC, Polverini PJ, et al. Thiol-containing compounds inhibit the production of monocyte/macrophage-derived angiogenic activity. Agents Actions 1991; 34, 350-357.
68. Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992; 175, 1135-1138.
69. Oliver SJ, Banquerigo ML, Brahn E. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol 1994; 157, 291-299.
70. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell Immunol 1995; 166, 196-206.
71. Storgard CM, Stupack DG, Jonczyk A et al. Decreased angiogenesis and arthritic disease in rabbits treated with an alphabeta3 antagonist. J Clin Invest 1999; 103, 47-54.